Microscopic polyangiitis is a rare blood vessel disorder that requires careful medical attention. Understanding treatment options—both currently approved therapies and those being studied in clinical trials—can help patients and families navigate the complex journey of managing this condition.

How Treatment Helps Control Blood Vessel Inflammation

When microscopic polyangiitis (MPA) strikes, the body’s immune system mistakenly attacks its own small blood vessels, causing widespread inflammation. The main goal of treatment is to calm this immune system overreaction, protect vital organs like the kidneys and lungs, and help patients return to a more normal life. Treatment isn’t just about controlling symptoms—it’s about preventing serious organ damage that can occur when inflammation goes unchecked.^[1]

Treatment decisions depend heavily on how severe the disease is when diagnosed and which organs are affected. Some patients may have mild symptoms affecting primarily the skin or joints, while others face life-threatening complications such as rapidly failing kidneys or bleeding in the lungs. The approach to therapy takes into account the patient’s age, overall health, and how active the disease appears to be.^[3]

Because microscopic polyangiitis is a rare condition—affecting only about 13 to 19 people per million—specialized expertise is essential. Medical societies have developed treatment guidelines based on decades of research and clinical experience. At the same time, researchers continue to explore new therapies through clinical trials, seeking treatments that are more effective and cause fewer side effects than traditional options.^[1]

The treatment journey typically unfolds in two distinct phases. The first phase, called induction therapy, uses powerful medications to quickly bring the disease under control. Once the inflammation settles down and symptoms improve, patients move to a second phase called maintenance therapy, which uses gentler medications over a longer period to prevent the disease from flaring up again.^[3]

Standard Treatment Approaches Used Today

The cornerstone of microscopic polyangiitis treatment involves medications that suppress the immune system. These drugs help stop the body from attacking its own blood vessels. The specific combination of medicines depends on how severe the disease is when first detected.^[6]

For patients with mild disease, doctors typically prescribe corticosteroids (such as prednisone) combined with either rituximab or methotrexate. Corticosteroids are powerful anti-inflammatory drugs that work quickly to reduce swelling and inflammation throughout the body. Rituximab is a type of antibody that targets specific immune cells called B-cells, which play a role in the abnormal immune response. Methotrexate suppresses the overall activity of the immune system, helping to prevent it from attacking blood vessels.^[6]

When microscopic polyangiitis is severe—especially when vital organs like the kidneys or lungs are seriously affected—treatment becomes more aggressive. In these cases, doctors use high doses of corticosteroids combined with either rituximab or another powerful drug called cyclophosphamide. Cyclophosphamide works by interfering with the growth and multiplication of immune cells that contribute to blood vessel inflammation.^[6]

The typical starting dose of prednisone is 1 milligram per kilogram of body weight per day, continued for about one month. If the patient shows significant improvement, the dose is gradually reduced by 5 milligrams per week. Once the daily dose reaches 10 milligrams, doctors may switch to a schedule where patients take 10 milligrams every other day. This gradual reduction helps minimize side effects while maintaining disease control.^[11]

Cyclophosphamide is typically started at a dose of 1.5 to 2 milligrams per kilogram per day. Doctors carefully monitor patients taking this medication because it can cause the white blood cell count to drop too low, making patients more vulnerable to infections. Regular blood tests help ensure the medication stays within a safe range.^[11]

Once the disease enters remission—meaning symptoms have improved and test results show the inflammation is under control—patients transition to maintenance therapy. Rituximab has become the preferred medication for this phase. This drug helps prevent relapses, which are unfortunately common in microscopic polyangiitis. Some patients may receive alternative maintenance medications such as azathioprine or mycophenolate if rituximab is not suitable for them.^[6]

For certain patients with severe kidney problems or dangerous bleeding in the lungs, doctors may recommend an additional treatment called plasma exchange. This procedure works like a blood filtering system. Blood is removed from the patient, the liquid portion (plasma) is separated out and discarded, and the blood cells are returned to the patient along with replacement fluid. The goal is to remove harmful antibodies and inflammatory substances from the bloodstream. However, recent studies have shown mixed results about how much this procedure helps, so doctors carefully select which patients might benefit most.^[6]

Common Side Effects of Standard Treatment

All medications used to treat microscopic polyangiitis can cause side effects, some of which can be serious. Corticosteroids like prednisone, especially when used at high doses or for extended periods, can lead to weight gain, high blood sugar (which may cause diabetes), high blood pressure, bone thinning (osteoporosis), mood changes, trouble sleeping, and increased risk of infections. Long-term use may also cause cataracts and an accumulation of fat in certain areas of the body.^[1]

Cyclophosphamide carries risks including increased vulnerability to infections due to low white blood cell counts, bladder problems (including blood in the urine), nausea, hair loss, and over the long term, an increased risk of certain cancers and infertility. Doctors monitor patients closely with regular blood tests to watch for these complications.^[3]

Rituximab can cause infusion reactions—symptoms that occur while the medication is being given or shortly after. These may include fever, chills, itching, rash, difficulty breathing, or changes in blood pressure. Most of these reactions are mild, but occasionally they can be severe. Doctors give other medications before rituximab infusions to reduce the risk of reactions. There’s also a risk of infections and, rarely, reactivation of hepatitis B virus in people who have previously been exposed to this virus.^[13]

Methotrexate can cause nausea, mouth sores, liver problems, and low blood counts. Patients taking this medication need regular blood tests to monitor liver function and blood cell counts. It’s extremely important that women and men taking methotrexate avoid pregnancy, as this drug can cause serious birth defects.^[12]

Research has shown that in the first year of treatment for microscopic polyangiitis and related conditions, 59% of deaths were related to treatment side effects rather than the disease itself, with infections and low white blood cell counts being the most serious problems. This sobering fact has driven researchers to search for treatments that are equally effective but safer.^[11]

Promising Therapies Being Tested in Clinical Trials

Researchers around the world are working to develop new treatments for microscopic polyangiitis that might be more effective or cause fewer side effects than current options. Clinical trials—carefully controlled research studies involving volunteer patients—are the way these new therapies are tested to determine if they’re safe and effective.^[3]

Avacopan: A Steroid-Sparing Alternative

One of the most significant recent advances in microscopic polyangiitis treatment is a drug called avacopan. This medication works differently from traditional immunosuppressive drugs. It blocks a specific part of the immune system called the C5a receptor, which plays a key role in the inflammatory process that damages blood vessels. By blocking this receptor, avacopan can reduce inflammation without suppressing the entire immune system.^[11]

The ADVOCATE trial was a major clinical study that tested avacopan in 331 patients with microscopic polyangiitis and a related condition called granulomatosis with polyangiitis. Researchers compared avacopan to prednisone, with both groups also receiving standard immunosuppressive therapy (either cyclophosphamide followed by azathioprine, or rituximab). The results were promising: avacopan worked at least as well as prednisone at 24 weeks and actually worked better than prednisone at 52 weeks in helping patients achieve complete remission of their disease.^[11]

The U.S. Food and Drug Administration has approved avacopan as an add-on treatment for severe microscopic polyangiitis and granulomatosis with polyangiitis, to be used in combination with other immunosuppressive medications. European medical societies suggest considering avacopan as part of a strategy to reduce patients’ exposure to high doses of corticosteroids, potentially avoiding many steroid-related side effects. However, avacopan is not currently approved as a complete replacement for steroids.^[11]

Clinical trials have shown that patients taking avacopan may experience side effects including nausea, headache, diarrhea, vomiting, upper respiratory infections, and high blood pressure. Serious liver problems have occurred in some patients. Doctors need to monitor liver function tests regularly in patients taking this medication.^[12]

Optimizing Rituximab Treatment

While rituximab is already an approved standard treatment, researchers continue to study the best ways to use this medication. Clinical trials are exploring different dosing schedules and comparing rituximab to other treatments to determine which approach works best for different groups of patients.^[13]

Rituximab was the first medication approved by the U.S. Food and Drug Administration specifically for treating microscopic polyangiitis and granulomatosis with polyangiitis in patients ages 2 years and above. It’s given through an intravenous infusion, meaning the medication drips into a vein over several hours. For microscopic polyangiitis, the typical treatment involves infusions given at regular intervals, combined with corticosteroids.^[13]

Studies have found that rituximab is particularly valuable for preventing disease relapses. Research comparing different types of patients has shown that those with antibodies against a protein called PR3 (proteinase 3) tend to have more relapses than those with antibodies against MPO (myeloperoxidase). Some researchers are investigating whether the type of antibody a patient has should influence treatment decisions, though current guidelines generally recommend the same treatments regardless of antibody type.^[15]

Clinical Trial Phases Explained

When researchers develop a new treatment, it must go through several phases of testing before it can be approved for general use. Phase I trials are small studies focused primarily on safety. Researchers want to know what dose of the medication is safe to use and what side effects might occur. These trials usually involve only a small number of patients, often those whose disease hasn’t responded to other treatments.^[3]

Phase II trials involve more patients and focus on whether the treatment actually works against the disease. Researchers look at whether symptoms improve, blood tests show less inflammation, and organ function stabilizes or improves. These studies help determine the right dose to use and provide more information about side effects.^[3]

Phase III trials are large studies that compare the new treatment directly to current standard treatments. These trials provide the strongest evidence about whether a new therapy is safe and effective. The ADVOCATE trial of avacopan was a Phase III trial. Hundreds of patients participate in these studies, often at multiple medical centers across different countries.^[11]

Clinical trials for microscopic polyangiitis are conducted at specialized medical centers in Europe, the United States, and other regions. Not every patient is eligible for every trial—researchers set specific criteria about disease severity, age, prior treatments, and other factors. Patients interested in participating in a clinical trial should discuss this possibility with their doctor.^[3]

Other Medications Under Investigation

Beyond avacopan and rituximab, researchers are exploring other medications that might help treat microscopic polyangiitis. Some trials are testing drugs that target different parts of the immune system or inflammatory pathways. Others are investigating whether medications already approved for other autoimmune diseases might also help patients with microscopic polyangiitis.^[12]

For example, trials have examined drugs that block a chemical messenger called TNF (tumor necrosis factor), which promotes inflammation. Other studies have looked at medications such as tocilizumab and sarilumab, which block another inflammatory signal called interleukin-6. Mepolizumab, which targets cells called eosinophils, and mycophenolate, another immunosuppressive drug, have also been studied in patients with vasculitis.^[12]

Intravenous immunoglobulin (IVIG), a treatment that involves giving concentrated antibodies from healthy donors, has been used in some patients whose disease doesn’t respond to standard treatments. While not a cure, IVIG may help in certain situations, though more research is needed to determine which patients benefit most.^[11]

Monitoring and Long-Term Care

Treatment for microscopic polyangiitis doesn’t end when symptoms improve. Ongoing monitoring is essential because the disease can flare up again even after successful treatment. Regular follow-up visits allow doctors to detect early signs of relapse and adjust treatment before serious problems develop.^[21]

Monitoring typically includes blood tests to check kidney function, look for signs of inflammation, and measure levels of ANCA antibodies. Urine tests help detect early kidney problems by showing if protein or blood cells are leaking into the urine. Some patients need periodic imaging studies to check their lungs or other organs. Doctors also monitor for side effects of medications and complications that can develop over time.^[1]

Patients taking immunosuppressive medications have a higher risk of infections because their immune system isn’t functioning normally. Doctors may recommend preventive antibiotics for certain patients, especially those at high risk. Vaccination is important but must be carefully timed because some vaccines don’t work as well in people taking immunosuppressive drugs, and certain types of vaccines shouldn’t be given during treatment.^[21]

Despite successful initial treatment, relapses occur in many patients with microscopic polyangiitis. When the disease becomes active again, treatment approaches are similar to those used for initial diagnosis. Most patients receive another course of induction therapy to bring the disease back under control, followed by adjusted maintenance therapy. Rituximab is often the preferred choice for treating relapses.^[11]

For patients whose disease doesn’t respond adequately to initial treatment (called refractory disease), doctors may need to try different medication combinations or consider plasma exchange. These challenging cases often require consultation with specialists who have extensive experience treating vasculitis.^[11]

Most Common Treatment Methods

• Corticosteroids
  • Prednisone is the most commonly used corticosteroid, typically started at 1 mg/kg per day
  • Reduces inflammation throughout the body quickly
  • Dose is gradually decreased over several months as symptoms improve
  • Reduced-dose regimens (about 55% of standard dose) may cause fewer side effects while remaining effective
• Immunosuppressive Medications
  • Rituximab targets B-cells in the immune system and is given by intravenous infusion
  • Cyclophosphamide interferes with immune cell growth, typically used for severe disease
  • Methotrexate suppresses overall immune system activity, often used for milder cases
  • Azathioprine and mycophenolate are commonly used for maintenance therapy after remission
• Complement Inhibitors
  • Avacopan blocks the C5a receptor to reduce inflammation without broadly suppressing immunity
  • FDA-approved as add-on therapy for severe microscopic polyangiitis
  • May allow reduction in corticosteroid use and associated side effects
  • Works as well as or better than prednisone in clinical trials
• Plasma Exchange
  • Blood filtering procedure that removes harmful antibodies and inflammatory substances
  • Considered for patients with severe kidney impairment or lung bleeding
  • Benefits are being re-evaluated based on recent clinical trial results
  • Reserved for selected severe cases
• Induction and Maintenance Therapy
  • Treatment divided into two phases: bringing disease under control (induction) and preventing relapse (maintenance)
  • Induction typically uses more aggressive medication combinations
  • Maintenance therapy uses lower doses or gentler medications for extended periods
  • Rituximab is preferred for maintenance to prevent relapses